Steven Nathan

Dec 10, 2024 | ajmc.com | Steven Nathan

OpinionVideoDecember 10, 2024Author(s): Current IPF cough treatments are often inadequate, highlighting the need for improved therapeutic strategies and a deeper understanding of underlying mechanisms. The study identifies potential pathways for novel interventions, which could significantly enhance patient quality of life by targeting specific mechanisms.

Dec 3, 2024 | businessandamerica.com | Steven Nathan

Dec 3, 2024 | ajmc.com | Steven Nathan

OpinionVideoDecember 3, 2024Author(s): The study focused on assessing oral nalbuphine extended release for cough relief in idiopathic pulmonary fibrosis patients. A randomized, double-blind, placebo-controlled trial design was employed to ensure robust and unbiased results. Nalbuphine treatment led to a significant reduction in cough frequency and severity compared to placebo, indicating its potential therapeutic benefit.

Nov 26, 2024 | ajmc.com | Steven Nathan

OpinionVideoNovember 26, 2024Author(s): Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH. Personalized treatment approaches are needed to address individual patient variability in IPF and PAH. Enhanced understanding of pathophysiological mechanisms is crucial for novel therapeutic target development.

Nov 19, 2024 | businessandamerica.com | Steven Nathan

OpinionVideoNovember 19, 2024 Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH. Personalized treatment approaches are needed to address individual patient variability in IPF and PAH. Enhanced understanding of pathophysiological mechanisms is crucial for novel therapeutic target development.